
    
      CT-P43, containing the active ingredient ustekinumab, is a human IgG1Îº monoclonal antibody
      that is being developed as a biosimilar medicinal product to the reference product, Stelara.
      The purpose of this study is to demonstrate similar efficacy and safety of CT-P43 and Stelara
      in patients with moderate to severe plaque psoriasis.
    
  